Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer

Curr Opin Investig Drugs. 2001 Mar;2(3):422-3.

Authors

N P Shah¹, C L Sawyers

Affiliation

¹ Department of Medicine, University of California, Los Angeles 90095-1678, USA.

PMID: 11575716

No abstract available

Publication types

Comparative Study
Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Clinical Trials, Phase I as Topic
Enzyme Inhibitors / therapeutic use
Forecasting
Gene Targeting
Genes, abl / drug effects*
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Piperazines / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / genetics
Pyrimidines / therapeutic use*
Remission Induction

Substances

Antineoplastic Agents
Benzamides
Enzyme Inhibitors
Piperazines
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases